KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Pacific Biosciences Of California (PACB) over the last 17 years, with Q1 2025 value amounting to $29.6 million.

  • Pacific Biosciences Of California's Gains from Investment Securities rose 744491.32% to $29.6 million in Q1 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 138098.55%. This contributed to the annual value of -$850000.0 for FY2024, which is 10564.41% down from last year.
  • Per Pacific Biosciences Of California's latest filing, its Gains from Investment Securities stood at $29.6 million for Q1 2025, which was up 744491.32% from -$2.0 million recorded in Q4 2024.
  • Over the past 5 years, Pacific Biosciences Of California's Gains from Investment Securities peaked at $29.6 million during Q1 2025, and registered a low of -$5.4 million during Q2 2022.
  • For the 5-year period, Pacific Biosciences Of California's Gains from Investment Securities averaged around $5.7 million, with its median value being $2.0 million (2023).
  • As far as peak fluctuations go, Pacific Biosciences Of California's Gains from Investment Securities tumbled by 27727.27% in 2024, and later skyrocketed by 744491.32% in 2025.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Gains from Investment Securities stood at $14.6 million in 2021, then tumbled by 68.59% to $4.6 million in 2022, then crashed by 76.08% to $1.1 million in 2023, then plummeted by 277.27% to -$2.0 million in 2024, then soared by 1617.95% to $29.6 million in 2025.
  • Its Gains from Investment Securities stands at $29.6 million for Q1 2025, versus -$2.0 million for Q4 2024 and $1.2 million for Q3 2024.